James P. Utz, M.D.

Closed for Enrollment

• Crossover From IDE Trial CLN0009, Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study, IDE G110066 (CROSSOVER) Rochester, Minn.

  The purpose of this study is to provide the lung volume reduction coil treatment procedure to patients who were randomized to the control group in study CLN0009, and obtain safety and effectiveness data on these patients.

• Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis (IPF): A Randomized, Double-blind, Placebo-controlled, 52-week Dose-ranging Study (ESTAIR) Rochester, Minn.

  Primary Objective: To evaluate, in comparison with placebo, the efficacy of 2 dose levels of SAR156597 administered subcutaneously during 52 weeks on lung function of patients with Idiopathic Pulmonary Fibrosis (IPF). Secondary Objectives: To evaluate the efficacy of 2 dose levels of SAR156597 compared to placebo on IPF disease progression. To evaluate the safety of 2 dose levels of SAR156597 compared to placebo in patients with IPF.

• Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study (RENEW) Rochester, Minn.

  Multicenter, randomized, assessor-blinded controlled study of safety and effectiveness of the PneumRx, Inc. RePneu Lung Volume Reduction Coil (RePneu LVRC) System